Can we safely skip the shock test during heart device implant?

NCT ID NCT03495297

Completed Knowledge-focused Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 24, 2026

Summary

This study looked at whether it's safe to skip the defibrillation test when implanting a subcutaneous implantable cardioverter-defibrillator (S-ICD). The test involves purposely triggering a dangerous heart rhythm to make sure the device can stop it. About 965 people took part. The goal was to see if skipping the test leads to more failed shocks when the device is needed later.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Academic Medical Center Amsterdam

Amsterdam, Netherlands
Adventh Health System

Orlando, Florida, 32803, United States
Albert Schweitzer Ziekenhuis

Dordrecht, Netherlands
Asklepios Kliniken

Hamburg, Germany
Barts Health NHS Trust of the Royal London Hospital

London, EC1A 7BE, United Kingdom
Basildon and Thurrock Univerity Hospital NHS Foundation Trust

Basildon, United Kingdom
Blackpool Victoria Hospital NHS Foundation Trust

Blackpool, United Kingdom
Canisius Wilhelmina Ziekenhuis

Nijmegen, Netherlands
Catharina Ziekenhuis

Eindhoven, Netherlands
CorVita Science Foundation

Chicago, Illinois, 60605, United States
Emory University Hospital

Atlanta, Georgia, 30322, United States
Englewood Hospital and Medical Center

Englewood, New Jersey, 07631, United States
Erlanger Health System

Chattanooga, Tennessee, 37403, United States
Flevoziekenhuis

Almere Stad, Netherlands
Heart and Chest Hospital NHS Foundation Trust

Liverpool, United Kingdom
Icahn School of Medicine at Mount Sinaï

New York, New York, 10029, United States
Isala Klinieken

Zwolle, Netherlands
Manchester Heart Center, Manchester Royal Infirmary

Manchester, M13 9WL, United Kingdom
Medisch Centrum Leeuwarden

Leeuwarden, Netherlands
Mount Sinai Beth Israel

New York, New York, 10003, United States
OLVG

Amsterdam, Netherlands
Oxford University Hospitals NHS Foundation Trust

Oxford, OX3 7LE, United Kingdom
Royal Papworth Hospital NHS Foundation Trust

Cambridge, United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital

Sheffield, United Kingdom
Spaarne Gasthuis

Haarlem, Netherlands
St Antonius Ziekenhuis

Nieuwegein, Netherlands
The Royal Wolverhampton NHS Trust, the New Cross Hospital

Wolverhampton, United Kingdom
UMCG

Groningen, Netherlands
Universitätsklinikum Mannheim

Mannheim, Germany
Universitätsklinikum Schleswig-Holstein

Kiel, Germany
Universitätsklinikum Schleswig-Holstein, Campus Lübeck

Lübeck, Germany
Universitätsklinikum Würzburg

Würzburg, Germany

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

procedure: subcutaneous implantable cardioverter-defibrillator (S-ICD) implantation with or without defibrillation testing

What this could lead to

If skipping the defibrillation test proves safe, future S-ICD implants could be simpler, faster, and less painful for patients.

What could go wrong

This is a completed study, but skipping the test might still miss some device issues. Results may not apply to all patients or devices.

Conditions

The condition(s) this trial relates to.

cardiac rhythm disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VENTRICULAR ARRYTHMIA